CD109 Monoclonal Antibody (HU17), eBioscience™, Invitrogen™

Description

• Description: The HU17 monoclonal antibody reacts with human CD109, also known as the platelet-specific Gov antigen
• CD109, a GPI-anchored monomeric glycoprotein, exists in two isoforms of 120 and 150 kDa, which are proteolytically degraded from a 170 kDa form
• CD109 is expressed on activated T cells, activated platelets and endothelial cells
• CD109 expression is also found on a subset of CD34+ cells in adult and fetal bone marrow which contain megakaryocyte, myeloid, erythroid and multilineage progenitors, as well as pluriopotent hematopoietic stem cells
• Recently, it has been demonstrated that CD109 is expressed on a variety of human cancer cell lines, and also lung and esophogeal cell carcinomas
• In addition, CD109 was recently found to be a negative regulator of TGF-beta in keratinocytes
• Applications Reported: This HU17 antibody has been reported for use in flow cytometric analysis, and immunoprecipitation
• Applications Tested: This HU17 antibody has been tested by flow cytometric analysis of normal human peripheral blood
• This can be used at less than or equal to 0.25 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• CD109 is a member of the alpha2-macroglobulin/complement superfamily
• The encoded GPI-linked glycoprotein is found on the cell surface of platelets, activated T-cells, and endothelial cells
• The protein binds to and negatively regulates signaling of transforming growth factor beta (TGF-beta).